免疫检查点抑制剂在小细胞肺癌治疗中的应用

doi:10.3760/cma.j.cn371439-20210305-00148

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (12): 747-750.doi: 10.3760/cma.j.cn371439-20210305-00148

免疫检查点抑制剂在小细胞肺癌治疗中的应用

曹纯¹, 何文琪², 晏军¹()

¹四川省自贡市第一人民医院肿瘤科 643000
²四川省自贡市第四人民医院放射科 643000

收稿日期:2021-03-05 修回日期:2021-03-28 出版日期:2021-12-08 发布日期:2022-01-12
通讯作者: 晏军 E-mail:ccyk640@126.com

Application of immune checkpoint inhibitors in the treatment of small cell lung cancer

Cao Chun¹, He Wenqi², Yan Jun¹()

¹Department of Oncology, Zigong First People's Hospital of Sichuan Province, Zigong 643000, China
²Department of Radiology, Zigong Fourth People's Hospital of Sichuan Province, Zigong 643000, China

Received:2021-03-05 Revised:2021-03-28 Online:2021-12-08 Published:2022-01-12
Contact: Yan Jun E-mail:ccyk640@126.com

摘要/Abstract

摘要：

免疫检查点抑制剂(ICI)的出现改变了抗肿瘤治疗格局,也为小细胞肺癌(SCLC)的治疗带来了新的希望,目前研究最广泛的ICI主要有程序性死亡受体/配体-1和细胞毒性T淋巴细胞抗原-4。阿替利珠单抗被推荐用于广泛期SCLC的一线治疗,帕博利珠单抗被推荐用于广泛期SCLC的三线治疗,ICI在SCLC的二线及维持治疗方面暂无突破。

关键词: 小细胞肺癌, 免疫检查点抑制剂, PD-1, PD-L1, CTLA-4

Abstract:

The emergence of immune checkpoint inhibitors (ICIs) have changed the pattern of anti-tumor therapy and brought new hope to the treatment of small cell lung cancer (SCLC). Currently, ICIs are most widely studied mainly include programmed death-1/ligand-1 and cytotoxic T-lymphocyte antigen-4. Altezumab is recommended for the first-line treatment of extensive SCLC, while pebrizizumab is recommended for the third-line treatment of extensive SCLC. There has been no breakthrough in the second-line and maintenance treatment of SCLC with ICIs.

Key words: Small cell lung carcinoma, Immune checkpoint inhibitors, PD-1, PD-L1, CTLA-4

曹纯, 何文琪, 晏军. 免疫检查点抑制剂在小细胞肺癌治疗中的应用[J]. 国际肿瘤学杂志, 2021, 48(12): 747-750.

Cao Chun, He Wenqi, Yan Jun. Application of immune checkpoint inhibitors in the treatment of small cell lung cancer[J]. Journal of International Oncology, 2021, 48(12): 747-750.

参考文献 21

[1]	Oronsky B, Reid TR, Oronsky A, et al. What's new in SCLC? A review[J]. Neoplasia, 2017,19(10):842-847. DOI: 10.1016/j.neo.2017.07.007.
[2]	Qin H F, Wang F, Liu H, et al. New advances in immunotherapy for non-small cell lung cancer[J]. Am J Transl Res, 2018,10(8):2234-2245.
[3]	Li Y, Li F, Jiang F, et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints[J]. Int J Mol Sci, 2016,17(7):1151. DOI: 10.3390/ijms17071151.
[4]	Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC)[J]. Pharmacol Ther, 2017,180:16-23. DOI: 10.1016/j.pharmthera.2017.06.002.
[5]	Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. New Engl J Med, 2012,366(26):2455-2465. DOI: 10.1056/NEJMoa1200694.
[6]	Wieder T, Eigentler T, Brenner E, et al. Immune checkpoint blockade therapy[J]. J Allergy Clin Immunol, 2018,142(5):1403-1414. DOI: 10.1016/j.jaci.2018.02.042.
[7]	Reck M, Heigener D, Reinmuth N. Immunotherapy for small-cell lung cancer: emerging evidence[J]. Future Oncol, 2016: 12(7):931-943. DOI: 10.2217/fon-2015-0012.
[8]	Horn L, Mansfeld AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018,379(23):2220-2229. DOI: 10.1056/NEJMoa1809064.
[9]	Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase ⅢKEYNOTE-604 study[J]. J Clin Oncol, 2020,38(21):2369-2379. DOI: 10.1200/JCO.20.00793.
[10]	Leal T, Wang Y, Dowlati A, et al. Randomized phase Ⅱ clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161[J]. J Clin Oncol, 2020,38(suppl_15):9000. DOI: 10.1200/JCO.2020.38.15_suppl.9000.
[11]	Reck M, Luft A, Szczesna A, et al. Phase Ⅲ randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinm in extensive-stage small-cell lung cancer[J]. J Clin Oncol, 2016,34(31):3740-3748. DOI: 10.1200/JCO.2016.67.6601.
[12]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinu-metoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019,394(10212):1929-1939. DOI: 10.1016/s0140-6736(19)32222-6.
[13]	O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase Ⅲ trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer[J]. J Clin Oncol, 2006,24(34):5441-5447. DOI: 10.1200/JCO.2006.06.5821.
[14]	Reck M, Vicente D, Ciuleanu T, et al. Efficacy and safety of ni-volumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331[J]. Ann Oncol, 2018,29(10_Suppl):43. DOI: 10.1093/annonc/mdy511.004.
[15]	Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab inrecurrent small-cell lungcancer (CheckMate032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol, 2016,17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5.
[16]	Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive stage small cell lung cancer: results from the phase Ⅰb KEY-NOTE028 study[J]. J Clin Oncol, 2017,35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069.
[17]	Chung HC, Lopez-Martin JA, Kao SCH, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158[J]. J Clin Oncol, 2018,36(Suppl_15):8506. DOI: 10.1200/JCO.2018.36.15_suppl.8506.
[18]	Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase Ⅱ study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)[J]. J Thorac Oncol. 2018,13(9):1393-1399 DOI: 10.1016/j.jtho.2018.05.002.
[19]	Riaz SP, Lüchtenborg M, Coupland VH, et al. Trends in incidence of small cell lung cancer and all lung cancer[J]. Lung Cancer, 2012,75(3):280-284. DOI: 10.1016/j.lungcan.2011.08.004.
[20]	Owonikoko TK, Kim HR, Govindan R, et al. Nivolumab (nivo) plus ipilimumab(ipi), nivo, or placebo(pbo) as maintenance therapy in patients(pts) with extensive disease small cell lung can-cer(ED-SCLC) after first-line(1L) platinum-based chemotherapy(chemo): results from the double-blind, randomized phase Ⅲ CheckMate 451 study[J]. Ann Oncol, 2019, 30(Suppl_2): ii77-ii80. DOI: 10.1093/annonc/mdz094.
[21]	Peters S, Pujol JL, Dafni U, et al. Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: results from the ETOP/IFCT4-12 STIMULI trial[J]. Ann Oncol, 2020,31(S4):S1211. DOI: 10.1016/j.annonc.2020.08.2326.

免疫检查点抑制剂在小细胞肺癌治疗中的应用

Application of immune checkpoint inhibitors in the treatment of small cell lung cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[2]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[3]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[4]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[5]	陈欣祎, 翁一鸣, 魏家燕, 王劲松, 彭敏. 免疫检查点抑制剂在复发或转移性头颈部鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(9): 553-557.
[6]	邓隽军, 赵大勇, 李淼. 免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素[J]. 国际肿瘤学杂志, 2023, 50(9): 564-568.
[7]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[8]	过慈良, 江春平, 吴俊华. 肠道菌群与肿瘤免疫治疗[J]. 国际肿瘤学杂志, 2023, 50(7): 432-436.
[9]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[10]	顾安琴, 龙金华, 金风. 鼻咽癌免疫治疗的临床研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 299-303.
[11]	王雅倩, 杜逸玮, 王兴, 贾军梅. 小细胞肺癌免疫治疗预后预测指标研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 179-182.
[12]	曹晓辉, 于荭, 李万湖. 基于CT的影像组学分析在预测和鉴别治疗相关性肺炎中的应用[J]. 国际肿瘤学杂志, 2023, 50(2): 107-111.
[13]	黄锐, 张允清. 安罗替尼单药在PS评分差的广泛期小细胞肺癌二线治疗中的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(12): 705-710.
[14]	焦盼盼, 薛丽娟, 詹娟. 免疫检查点抑制剂相关不良反应的危险因素与预测因素[J]. 国际肿瘤学杂志, 2023, 50(12): 739-744.
[15]	刘绍平, 罗汉传, 林书瀚, 罗家辉. 中晚期肝细胞癌介入及系统治疗的现状与研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 758-762.